Primary Recipient

FRONTIER SCIENCE & TECHNOLOGY RESEARCH FOUNDATION, INC.

Amount

$785,220.00

Award Date

7/17/2009

Administering Agency

Health and Human Services, Department of / National Institutes of Health

CDFA Number

93.701

CDFA Program Title

Trans-NIH Recovery Act Research Support

Description

The E1508 randomized phase II clinical trial will evaluate the combination of cisplatin and etoposide versus cisplatin and etoposide with either GDC-0449 or IMC-A12 for selection of the regimen with superior anti-cancer activity (primary endpoint is progr

Recipients Connected to Award

Recipient	Role	Amount
SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH	Sub-recipient	$415,587.00
FRONTIER SCIENCE & TECHNOLOGY RESEARCH FOUNDATION, INC.	Primary recipient	$264,783.00
NORTHWESTERN UNIVERSITY	Sub-recipient	$89,225.00
DANA-FARBER CANCER INSTITUTE, INC.	Sub-recipient	$15,625.00